BPI-21668
/ Betta Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
April 22, 2022
A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of BPI-21668
(clinicaltrials.gov)
- P1 | N=60 | Recruiting | Sponsor: Betta Pharmaceuticals Co., Ltd.
New P1 trial • Oncology • Solid Tumor • PIK3CA
1 to 1
Of
1
Go to page
1